New research shows that patients with advanced cardiovascular disease who took Mounjaro or Zepbound had a lower risk of death than similar patients who did not. The findings add to growing interest in tirzepatide drugs as more than weight-loss treatments, and they are prompting doctors to reassess how these medicines …